Search results for: 'workforce identity ad access management'

The biopharma industry has been evolving over the past few decades. This study analyses the top ten trends that will impact the future of the biopharma industry through 2040.The future of biopharma will be driven by innovation in AI and ML, particularly generative AI, and by advancements in translational medicine and synthetic biology. Future clini...

19 Sep 2018  |  North America  |  Market Research

Global Biologics Contract Development and Manufacturing Organization (CDMO) Market, Forecast to 2022

Investments in Single Use/Disposable Technologies to Capitalize on Growth Opportunities in High-value Low-volume Biologics

Infographics

×

Key Issues Addressed

The global pharmaceutical industry is evolving with the rising need for novel therapies in the changing disease landscape. As a result of rising prevalence of chronic infectious diseases as well as growing cancer incidence, market needs are shifting from traditional small molecules to large molecules. This study presents an overview of the global b...

Worldwide cancer incidence is expected to exceed 35 million new cases by 2050, a 77% rise from the 20 million cases in 2022. Alcohol intake, tobacco usage, obesity, and air pollution are the main causes of this increase. Cancer studies today emphasize cell and gene therapy, antibody-drug conjugates (ADCs), checkpoint inhibitors, and multi-specific...

21 Mar 2025  |  Global  |  Market Research

Pharmaceutical Clinical Contract Peripheral Services, Global, 2025–2030

The CRO Industry is Witnessing Transformational Growth Due to Industry Convergence and an Increasing Reliance on the Functional Service Provider (FSP) Model

Infographics

×

As trial volumes normalize after the COVID-19 pandemic, pharma and biopharma companies are re-focusing on their drug development pipelines. As a result, the market has been creating an increasing number of clinical trial outsourcing opportunities for CROs, with these service providers also refining their processes to ensure better clinical trial tu...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations transforming respiratory medicine, liver regeneration, metabolic disease management, infectious disease therapeutics, neurological disorders, cardiovascular risk reduction, oncology workflows, and nex...

As the industry continues to innovate across novel small- and large-molecule therapies, including RNA-targeted small molecules, cell and gene therapies, and mRNA therapies, pharma sponsors increasingly rely on partners for technology access, database generation and analysis, and preclinical and clinical research.These disruptions continue to drive ...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping diagnostics, therapeutics, and clinical workflows across infectious diseases, women’s health, metabolic disorders, neurodegeneration, oncology, rare diseases, and musculoskeletal care. It hi...

The SCOPE Summit 2026, held in Orlando, Florida, from February 2 to 5, 2026, highlighted the dominance of small- to mid-segment companies and specialized CROs focusing on specific therapy areas or aspects of clinical trials, such as bioanalysis. With more than 4,000 attendees, 630 speakers, and 300 exhibitors, SCOPE 2026 reinforced its position as ...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) delivers provides strategic insights into breakthrough innovations shaping the future of healthcare, life sciences, and precision therapeutics. It highlights advances in AI-enabled diagnostics, metabolic reprogramming, small molecules, deep proteomics, RNA disco...